Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Epistaxis, Blood Pressure
Interventions
Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions
Pazopanib, Placebo oral capsule
Drug
Lead sponsor
Cure HHT
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Postoperative Pain
Interventions
RADA16 hydrogel
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Livingston, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Epistaxis
Interventions
Tranexamic Acid, 0.9% Sodium Chloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Heart Rate, Blood Pressure, Blood Loss During Surgery, Surgical Field
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
16 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced May 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
Conditions
Nasotracheal Intubation, Nasal Bleeding
Interventions
Nasotracheal intubation over a bougie, Conventional Nasotracheal Intubation
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
8 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Epistaxis
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 21, 2026, 8:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
Conditions
Epistaxis Nosebleed
Interventions
Nasal Compression Device, Routine Care
Device · Diagnostic Test
Lead sponsor
NasaClip
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced May 21, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers
Conditions
Postoperative Bleeding, Skin Cancer Face
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine), Control (1% lidocaine with 1:100,000 epinephrine)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Ecchymosis
Interventions
Arnica montana, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Endoscopic Sinus Surgery, Nasal Polyps
Interventions
Oxymetazoline, Epinephrine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Epistaxis
Interventions
Parker flex-tip nasotracheal tube, Standard nasotracheal tube
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 11 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
ALN-6400, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Submucosal Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced May 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Epistaxis
Interventions
2009-I-Epistaxis-1
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Epistaxis
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boardman, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced May 21, 2026, 8:59 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers
Conditions
Nasal Sinus; Inflammation, Opioid Abuse, Pain, Postoperative
Interventions
Ibuprofen 600Mg Tablet, Standard Regimen | Tylenol
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced May 21, 2026, 8:59 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
TER-1754, Placebo
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 8:59 PM EDT